| P-12/1 |
Aspirin
resistance in patients with myeloproliferative neoplasms
N. Candeo, S. Vettore , F. Tezza, I.
Bertozzi, ML. Randi (Padova) |
| P-12/2 |
Therapeutic
drug monitoring of imatinib in patients affected by chronic myeloid leukemia
M. Lastella, S. Galimberti, M. Polillo, M. Rousseau, E. Sordi, C.
Baratè, M. Petrini, R. Danesi, A. Di Paolo (Pisa) |
| P-12/3 |
Monitoring circulating deferasirox
levels in chronic myeloid thalassemic patients.
S. De Francia, D. Massano, E. Pirro, F.M. Piccione, M. Melania,
F. Francesco, A. Antonio (Torino) |
| P-12/4 |
Therapeutic drug monitoring of
imatinib in leukemic patients: comparison between an HPLC–UV method and an
LC-MS/MS method.
E. Pirro, S. De Francia, F.M. Piccione, R. Arvonio, G.
Muccioli, M. Ruoppolo, F. Di Carlo (Orbassano, Napoli) |
| P-12/5 |
Cytotoxic
activity of human iNKT cells against ostosarcoma
cells
S. Fallarini, T. Paoletti, G. Lombardi (Novara, novara) |
| P-12/6 |
Frequency and phenotype of circulating invariant NKT cells in
malignant pleural mesothelioma patients
E. Altomare, S. Fallarini, M. Botta, G. Lombardi (Novara, Casale
Monferrato) |
| P-12/7 |
CD4+CD25lowGITR+ cells: a novel human CD4+ regulatory T cell subset disregulated in
autoimmune diseases.
M.G. Petrillo, A. Alunno , R. Bianchini ,
O. Bistoni, S. Ronchetti, G. Nocentini, R. Gerli, C. Riccardi (Perugia) |
| P-12/8 |
Immunological evaluation of peptides derived from Bcr/Abl-Out of
Frame fusion protein in HLA A2.1 transgenic mice
C. Casnici, K. Crotta, G. Volpe, D. Lattuada, O. Marelli (Milano, Torino) |
| P-12/9 |
A de novo mutation in Caveolin-3 gene may confer
genetic susceptibility for long QT syndrome.
A.A. Nasti, F. Alessandrini, V. Lariccia, M. Pesaresi, A.
Tagliabracci, S. Amoroso (Ancona) |
| P-12/10 |
DNA vaccination against ERBB2
oncoantigen impairs oral tumor development.
G.N. Berta, A.E. Sprio, P. Salamone , F. Di Scipio, G. Forni, F. Cavallo (Torino) |
| P-12/11 |
A phase IV, randomized,
controlled, open-label, study on efficacy of Naltrexone combined with
psychotherapy for treatment of alcohol dependence (Diatrex 0709 Study).
F. Matttioli, C. Fucile, V. Marini, ML. Zuccoli, D. Barciocco,
A. Sumberaz, G. Testino, A. Martelli (Genova) |
| P-12/12 |
The effect of Omalizumab on exacerbation frequency,
corticosteroids intake and peripheral blood eosinophils count in atopic
asthmatic patients
L. Gallelli, G. Pelaia, P. Romeo, T. Renda, MT. Busceti, M. Marrazzo,
G. De Sarro, R. Maselli (Catanzaro) |
| P-12/13 |
Dissemination of clinical trial
results through clinical trial registers.
M. Vietri, S.
Benemei, C. Lupi, A. Xheka, P. Geppetti, A. Mugelli (Florence) |
| P-12/14 |
Combined oral
contraceptives induce epigenetic modifications and change in expression and activity of estrogen receptorsin monocyte-derived
macrophages
I. Campesi, M. Sanna, C. Carru, A. Zinellu, L. Rubattu, P. Bulzomi, G.
Seghieri, G. Tonolo, M. Palermo, G. Rosano, M. Marino, F. Franconi (Sassari,
Roma, Pistoia, Olbia) |
| P-12/15 |
Clinical
Reserach In Paediatrics: New Momentum And Critical Aspects
C.A. Rizzi, C. Conz, C. Fiorella (Milano) |
| P-12/16 |
A Model Of Randomized Controlled
Trial Applied To Clinical Procedures Rather Than To Drug Comparison: The
Hip-Hop Study In Very Preterm Infants With Hypotension
L. Gagliardi, R. Bellù, R. Zanini,
C.A.
Rizzi (Camaiore,
Lecco,
Milano) |
| P-12/17 |
Performance and tolerability of a medical device containing
hyaluronic acid and collagenase for the management of chronic venous ulcers
S.R. Georgescu, V. Clatici, S.H.
Morariu, I. Stoicescu, N. Giordan, F. Montanaro, D.F. Barattini (Bucurest,
Romania, Targu Mures Romania, Craiova Romania, Abano Terme) |
| P-12/18 |
Difference in
bioavailability of commercially available rifaximin equivalent drugs.
A. Giusti, A. Marzo, V. Lauro (Ligornetto,
Bologna) |